Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY
NCT ID: NCT00761787
Last Updated: 2009-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
800 participants
OBSERVATIONAL
2005-05-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Angioshield Study Feasibility II
NCT02543047
Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy
NCT02377648
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
NCT01327742
Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies
NCT05479305
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Heart transplanted subjects.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients (age ≥ 18years) receiving post-transplant care at the enrolling centers
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
XDx
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
XDx, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota
Minneapolis, Minnesota, United States
Columbia University Medical Center
New York, New York, United States
Texas Heart Institute
Houston, Texas, United States
Medizinische Universität Innsbruck, Klinische Abteilung für Herzchirurgie
Anichstrasse 35, Innsbruck, Austria
Medical University of Vienna (Medizinische Universität Wien)
Währinger Gürtel 18-20, Vienna, Austria
UZ Gasthuisberg
Herestraat 49, Leuven, Belgium
Toronto General Hospital
Toronto, Ontario, Canada
Hospital La Pitie
47 Bd de L, Paris, France
Herz- und Diabeteszentrum NRW
Georgstraße 11, Bad Oeynhausen, Germany
Medizinische Hochschule Hannover
Hanover, Carl-Neuberg-Str. 1, Germany
UKM - Medizinische Klinik und Poliklinik C (Kardiologie und Angiologie)
Albert-Schweitzer-Str. 33, Münster, Germany
Deutsches Herzzentrum Berlin
Augustenburger Platz, State of Berlin, Germany
Ospedali Riuniti di Bergamo
Largo Barozzi 1, Bergamo, Italy
Silesian Center for Heart Disease
Ul. Szpitalna 2, Zabrze, Poland
Hospital Juan Canalejo
As Xubias 84, La Coruna, Spain
Inselspital - Universitätsspital Bern Postfach 33
Schweizer Herz-und Gefässzentrum Bern, Canton of Bern, Switzerland
Papworth Hospital
Papworth Everard, Cambridge, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczynski M, Fiocchi R, Hoefer D, Colvin M, Deng MC, Leprince P, Elashoff B, Yee JP, Vanhaecke J. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J. 2016 Sep 1;37(33):2591-601. doi: 10.1093/eurheartj/ehv682. Epub 2016 Jan 7.
Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczynski M, Fiocchi R, Hoefer D, Deng M, Leprince P, Hiller D, Eubank L, Deljkich E, Yee JP, Vanhaecke J. Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients. BMC Cardiovasc Disord. 2015 Oct 9;15:120. doi: 10.1186/s12872-015-0106-1.
Crespo-Leiro MG, Zuckermann A, Bara C, Mohacsi P, Schulz U, Boyle A, Ross HJ, Parameshwar J, Zakliczynski M, Fiocchi R, Stypmann J, Hoefer D, Lehmkuhl H, Deng MC, Leprince P, Berry G, Marboe CC, Stewart S, Tazelaar HD, Baron HM, Coleman IC, Vanhaecke J. Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation. 2012 Dec 15;94(11):1172-7. doi: 10.1097/TP.0b013e31826e19e2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CARGO II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.